Know Cancer

or
forgot password

Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Malignant Glioma

Thank you

Trial Information

Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial

Inclusion Criteria


Inclusion criteria:

- Histologically confirmed diagnosis of a recurrent primary malignant glioma

- Life expectancy of at least 3 months with normal hematological, liver and renal
function

Exclusion criteria:

- Pregnant and lactating patients

- Participation in any investigating drug study within 4 weeks preceding treatment
start or concurrent treatment with any other anti-cancer therapy

- Gastrointestinal dysfunction that could alter absorption or motility

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

ST 01-402

NCT ID:

NCT00032903

Start Date:

March 2002

Completion Date:

October 2005

Related Keywords:

  • Malignant Glioma
  • Malignant Glioma, Camptothecin, Pharmacokinetics
  • Glioma

Name

Location

Rhode Island HospitalProvidence, Rhode Island  02903